Therapeutics
Utilities in treating difficult diseases
Cell therapies IVR therapies
market for IVR therapeutics to be as big as that for drug-based therapeutics. To overcome poten- tial challenges from the concept to the clinics, such as issues of efficiency, specificity and immuno- genicity, the advancement of this field requires a collective effort from researchers, clinicians, insti- tutes and companies. Given enough investment and commitment, the research in this promising area will ripen in the coming decade, forever rev- olutionising medicine.
DDW Drug therapies
Risk in development and commercialisation
Figure 5: New strategy: in vivo cell reprogramming therapies. The size of the area enclosed by each circle indicates how big the market for that type of treatment is. The dotted circle is the projected market for in vivo cell reprogramming therapies. The risk profiles and cost structures of development and commercialisation of IVR therapeutics are similar to those of drug-based therapies. However, by using a cell-based mechanism, IVR therapeutics can achieve therapeutic benefits that cannot be achieved by conventional drugs
those of drug-based therapies (Figure 5). However, by using a cell-based mechanism, IVR therapeutics can achieve therapeutic benefits that cannot be achieved by conventional drugs. In addition, the newly created product cells are sustainable. Therefore a short course of treatment can provide long-term clinical benefits. Moreover, contrary to most situations in cell or tissue transplantation, new product cells will not cause immune rejection. IVR can be applied to many disease areas, including diabetes, autoimmune diseases and stroke. As shown in Figure 5, we expect the future
Dr Shili Wu is Director of Technology at VivoScript, a US-based biotech company estab- lished to commercialise a disruptive innovation – IVR technology – in regenerative medicine. Messrs Jonathan Pang and Bobby Baravati are research associates at VivoScript. Mr Jun Bao is CEO of the company. Dr Yong Zhu is Vice President, Research and Business Development, at VivoScript.
Biocius Life Sciences BioTek Instruments, Inc Caliper Life Sciences, Inc CISBIO International SA DiscoveRx Corporation eBioscience, Inc ELRIG
Fluofarma
43 51 65 21 46
23,83 54 30
ADVERTISEMENT INDEX 38
GE Healthcare HTStec Ltd
Hudson Robotics, Inc ID Business Solutions Ltd
Life Technologies Corporation Luminex Corporation Millipore Corporation Mirus Bio LLC
33 72 16 8 6
37 89
PerkinElmer
Roche Applied Science Seahorse Bioscience, Inc Select Biosciences Ltd Tecan Schweiz AG
Thermo Fisher Scientific TTP LabTech Ltd
80 11 86
IBC IFC-3
24,OBC 4
90
Drug Discovery World Summer 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92